Publications

Falk Nimmerjahn on Google Scholar

5 Key Publications

  1. Lehmann, B., M. Biburger, C. Brückner, A. Ipsen-Escobedo, S. Gordan, C. Lehmann, D. Voehringer, T. Winkler, N. Schaft, D. Dudziak, H. Sirbu, G.F. Weber, and F. Nimmerjahn. 2017. Tumor location determines tissue-specific recruitmetn of tumor-associated macrophages and antibody-dependent immunotherapy response. Science Immunol 2:1-11.
  2. Kao, D., H. Danzer, M. Collin, A. Gross, J. Eichler, J. Stambuk, G. Lauc, A. Lux, and F. Nimmerjahn. 2015. A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors. Cell Rep 13:2376-2385.
  3. Nimmerjahn, F., S. Gordan, and A. Lux. 2015. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 36:325-336.
  4. Schwab, I., A. Lux, and F. Nimmerjahn. 2015. Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice. Cell Rep 13:610-620.
  5. Biburger, M., S. Aschermann, I. Schwab, A. Lux, H. Albert, H. Danzer, M. Woigk, D. Dudziak, and F. Nimmerjahn. 2011. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35:932-944.

Primary Publications (since 2012)

  • Lehmann, C., A. Baranska, G. Heidkamp, L. Heger, K. Neubert, J. Lühr, A. Hoffmann, K.C. Reimer, C. Brückner, S. Beck, M. Seeling, M. Kiessling, D. Soulat, A.B. Krug, J.V. Ravetch, J.H. Leusen, F. Nimmerjahn, and D. Dudziak. 2017. DC subset specific induction of T cell responses upon antigen uptake via Fc receptors in vivo. J Exp Med in press.
  • Lehmann, B., M. Biburger, C. Brückner, A. Ipsen-Escobedo, S. Gordan, C. Lehmann, D. Voehringer, T. Winkler, N. Schaft, D. Dudziak, H. Sirbu, G.F. Weber, and F. Nimmerjahn. 2017. Tumor location determines tissue-specific recruitmetn of tumor-associated macrophages and antibody-dependent immunotherapy response. Science Immunol 2:1-11.
  • Pfeifle, R., T. Rothe, N. Ipseiz, H.U. Scherer, S. Culemann, U. Harre, J.A. Ackermann, M. Seefried, A. Kleyer, S. Uderhardt, B. Haugg, A.J. Hueber, P. Daum, G.F. Heidkamp, C. Ge, S. Bohm, A. Lux, W. Schuh, I. Magorivska, K.S. Nandakumar, E. Lonnblom, C. Becker, D. Dudziak, M. Wuhrer, Y. Rombouts, C.A. Koeleman, R. Toes, T.H. Winkler, R. Holmdahl, M. Herrmann, S. Bluml, F. Nimmerjahn, G. Schett, and G. Kronke. 2017. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nature Immunol 18:104-113.
  • Hartholt, R.B., A. Wroblewska, E. Herczenik, I. Peyron, A. Ten Brinke, T. Rispens, M.A. Nolte, E. Slot, J.W. Claassens, F. Nimmerjahn, J.S. Verbeek, and J. Voorberg. 2017. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells. J Thromb Haemost15:329-340.
  • Van den Hoecke, S., K. Ehrhardt, A. Kolpe, K. El Bakkouri, L. Deng, H. Grootaert, S. Schoonooghe, A. Smet, M. Bentahir, K. Roose, M. Schotsaert, B. Schepens, N. Callewaert, F. Nimmerjahn, P. Staeheli, H. Hengel, and X. Saelens. 2017. Hierarchical and redundant roles of activating FcgammaRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies. J Virol
  • Wege, A.K., F. Weber, A. Kroemer, O. Ortmann, F. Nimmerjahn, and G. Brockhoff. 2017. IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget 8:2731-2744.
  • Brandsma, A.M., P.M. Hogarth, F. Nimmerjahn, and J.H. Leusen. 2016. Clarifying the Confusion between Cytokine and Fc Receptor „Common Gamma Chain“. Immunity 45:225-226.
  • Hartholt, R.B., A. Wroblewska, E. Herczenik, I. Peyron, A. Ten Brinke, T. Rispens, M.A. Nolte, E. Slot, J.W. Claassens, F. Nimmerjahn, J.S. Verbeek, and J. Voorberg. 2016. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells. J Thromb Haemost
  • Heidkamp, G., J. Sander, C. Lehmann, L. Heger, N. Eissing, A. Lux, S. Söder, A. Hartmann, J. Zenk, T. Ulas, N. McGovern, C. Alexiou, B.M. Spriewald, A. Mackensen, G. Schuler, B. Schauf, A. Forster, R. Repp, P.A. Fasching, A. Purbojo, R. Cesnjevar, E. Ullrich, F. Ginhoux, A. Schlitzer, F. Nimmerjahn, J.L. Schultze, and D. Dudziak. 2016. Human Lymphoid Organ Dendritic Cell Identity is predominantly dictated by ontogeny, not tissue microenvironment. Science Immunol 12:1-17.
  • Magorivska, I., L.E. Munoz, C. Janko, T. Dumych, J. Rech, G. Schett, F. Nimmerjahn, R. Bilyy, and M. Herrmann. 2016. Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells. Clin Exp Immunol 184:110-117.
  • Mihai, S., H. Albert, R.J. Ludwig, H. Iwata, L. Bjorck, M. Collin, and F. Nimmerjahn. 2016. In vivo enzymatic modulation of IgG antibodies prevents immune complex-dependent skin injury. Exp Dermatol
  • Nimmerjahn, F. 2016. Immunomodulation of immunothrombocytopenia. Semin Hematol 53 Suppl 1:S10-12.
  • Nimmerjahn, F. 2016. Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches. J Clin Immunol 36 Suppl 1:83-87.
  • Ortiz, D.F., J.C. Lansing, L. Rutitzky, E. Kurtagic, T. Prod’homme, A. Choudhury, N. Washburn, N. Bhatnagar, C. Beneduce, K. Holte, R. Prenovitz, M. Child, J. Killough, S. Tyler, J. Brown, S. Nguyen, I. Schwab, M. Hains, R. Meccariello, L. Markowitz, J. Wang, R. Zouaoui, A. Simpson, B. Schultes, I. Capila, L. Ling, F. Nimmerjahn, A.M. Manning, and C.J. Bosques. 2016. Elucidating the interplay between IgG-Fc valency and FcgammaR activation for the design of immune complex inhibitors. Science Transl Med 8:365ra158.
  • Stamatiades, E.G., M.E. Tremblay, M. Bohm, L. Crozet, K. Bisht, D. Kao, C. Coelho, X. Fan, W.T. Yewdell, A. Davidson, P.S. Heeger, S. Diebold, F. Nimmerjahn, and F. Geissmann. 2016. Immune Monitoring of Trans-endothelial Transport by Kidney-Resident Macrophages. Cell166:991-1003.
  • Biburger, M., I. Trenkwald, and F. Nimmerjahn. 2015. Three blocks are not enough–Blocking of the murine IgG receptor FcgammaRIV is crucial for proper characterization of cells by FACS analysis. Eur J Immunol 45:2694-2697.
  • Bruhl, H., J. Cihak, Y. Talke, M. Rodriguez Gomez, F. Hermann, N. Goebel, K. Renner, J. Plachy, M. Stangassinger, S. Aschermann, F. Nimmerjahn, and M. Mack. 2015. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis. Eur J Immunol 45:705-715.
  • Fickentscher, C., I. Magorivska, C. Janko, M. Biermann, R. Bilyy, C. Nalli, A. Tincani, V. Medeghini, A. Meini, F. Nimmerjahn, G. Schett, L.E. Munoz, L. Andreoli, and M. Herrmann. 2015. The Pathogenicity of Anti-beta2GP1-IgG Autoantibodies Depends on Fc Glycosylation. J Immunol Res 2015:638129
  • Gordan, S., M. Biburger, and F. Nimmerjahn. 2015. bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression. Immunol Rev 268:52-65.
  • Harre, U., S.C. Lang, R. Pfeifle, Y. Rombouts, S. Fruhbeisser, K. Amara, H. Bang, A. Lux, C.A. Koeleman, W. Baum, K. Dietel, F. Grohn, V. Malmstrom, L. Klareskog, G. Kronke, R. Kocijan, F. Nimmerjahn, R.E. Toes, M. Herrmann, H.U. Scherer, and G. Schett. 2015. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nature Commun 6:6651.
  • Hasenberg, A., M. Hasenberg, L. Mann, F. Neumann, L. Borkenstein, M. Stecher, A. Kraus, D.R. Engel, A. Klingberg, P. Seddigh, Z. Abdullah, S. Klebow, S. Engelmann, A. Reinhold, S. Brandau, M. Seeling, A. Waisman, B. Schraven, J.R. Gothert, F. Nimmerjahn, and M. Gunzer. 2015. Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes. Nature Methods 12:445-452.
  • Hirose, M., B. Tiburzy, N. Ishii, E. Pipi, S. Wende, E. Rentz, F. Nimmerjahn, D. Zillikens, R.A. Manz, R.J. Ludwig, and M. Kasperkiewicz. 2015. Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita. J Invest Dermatol 135:768-775.
  • Kao, D., H. Danzer, M. Collin, A. Gross, J. Eichler, J. Stambuk, G. Lauc, A. Lux, and F. Nimmerjahn. 2015. A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors. Cell Rep 13:2376-2385.
  • Lunemann, J.D., F. Nimmerjahn, and M.C. Dalakas. 2015. Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nature Rev Neurol 11:80-89.
  • Lux, A., and F. Nimmerjahn. 2015. No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer. Cancer Cell 27:10-11.
  • Muller, J., B. Lunz, I. Schwab, A. Acs, F. Nimmerjahn, C. Daniel, and L. Nitschke. 2015. Siglec-G Deficiency Leads to Autoimmunity in Aging C57BL/6 Mice. J Immunol 195:51-60.
  • Nimmerjahn, F. 2015. A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome. Eur J Immunol 45:2183-2190.
  • Nimmerjahn, F., S. Gordan, and A. Lux. 2015. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 36:325-336.
  • Quast, I., F. Cueni, F. Nimmerjahn, B. Tackenberg, and J.D. Lunemann. 2015. Deregulated Fcgamma receptor expression in patients with CIDP. Neurol Neuroimmunol Neuroinflamm 2:e148.
  • Quast, I., C.W. Keller, M.A. Maurer, J.P. Giddens, B. Tackenberg, L.X. Wang, C. Munz, F. Nimmerjahn, M.C. Dalakas, and J.D. Lunemann. 2015. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 125:4160-4170.
  • Schwab, I., A. Lux, and F. Nimmerjahn. 2015. Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice. Cell Rep 13:610-620.
  • Seeling, M., and F. Nimmerjahn. 2015. Releasing the brakes: targeting FcgammaRIIB on B cells to enhance antibody-dependent lymphoma immunotherapy. Cancer Cell 27:427-428.
  • Seeling, M., and F. Nimmerjahn. 2015. Unlocking the bone: Fcgamma-receptors and antibody glycosylation are keys to connecting bone homeostasis to humoral immunity. Ann Transl Med 3:163.
  • Stock, M., A. Distler, J. Distler, C. Beyer, G. Ruiz-Heiland, N. Ipseiz, M. Seeling, G. Kronke, F. Nimmerjahn, and G. Schett. 2015. Fc-gamma receptors are not involved in cartilage damage during experimental osteoarthritis. Osteoarthritis Cartilage 23:1221-1225.
  • Washburn, N., I. Schwab, D. Ortiz, N. Bhatnagar, J.C. Lansing, A. Medeiros, S. Tyler, D. Mekala, E. Cochran, H. Sarvaiya, K. Garofalo, R. Meccariello, J.W. Meador, 3rd, L. Rutitzky, B.C. Schultes, L. Ling, W. Avery, F. Nimmerjahn, A.M. Manning, G.V. Kaundinya, and C.J. Bosques. 2015. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A 112:E1297-1306.
  • Yamada, D.H., H. Elsaesser, A. Lux, J.M. Timmerman, S.L. Morrison, J.C. de la Torre, F. Nimmerjahn, and D.G. Brooks. 2015. Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Immunity 42:379-390.
    Biburger, M., A. Lux, and F. Nimmerjahn. 2014. How immunoglobulin G antibodies kill target cells: revisiting an old paradigm. Adv Immunol 124:67-94.
  • Bohm, S., D. Kao, and F. Nimmerjahn. 2014. Sweet and sour: the role of glycosylation for the anti-inflammatory activity of immunoglobulin G. Curr Top Microbiol Immunol 382:393-417.
  • Daeron, M., and F. Nimmerjahn. 2014. High amounts of specific antibodies are produced upon antigen stimulation during adaptive immune responses. Preface. Curr Top Microbiol Immunol 382:v – xi.
  • Kao, D., A. Lux, I. Schwab, and F. Nimmerjahn. 2014. Targeting B cells and autoantibodies in the therapy of autoimmune diseases. Semin Immunopathol 36:289-299.
  • Lux, A., M. Seeling, A. Baerenwaldt, B. Lehmann, I. Schwab, R. Repp, N. Meidenbauer, A. Mackensen, A. Hartmann, G. Heidkamp, D. Dudziak, and F. Nimmerjahn. 2014. A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep 7:236-248.
  • Neubert, K., C.H. Lehmann, L. Heger, A. Baranska, A.M. Staedtler, V.R. Buchholz, S. Yamazaki, G.F. Heidkamp, N. Eissing, H. Zebroski, M.C. Nussenzweig, F. Nimmerjahn, and D. Dudziak. 2014. Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. J Immunol192:5830-5838.
  • Nimmerjahn, F., and A. Lux. 2014. LILR-B1 blocks activating FcgammaR signaling to allow antibody dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 111:2404-2405.
  • Schulze, F.S., T. Beckmann, F. Nimmerjahn, A. Ishiko, M. Collin, J. Kohl, S. Goletz, D. Zillikens, R. Ludwig, and E. Schmidt. 2014. Fcgamma receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol 184:2185-2196.
    Schwab, I., A. Lux, and F. Nimmerjahn. 2014. Reply to – IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nature Rev Immunol 14:349.
  • Schwab, I., S. Mihai, M. Seeling, M. Kasperkiewicz, R.J. Ludwig, and F. Nimmerjahn. 2014. Broad requirement for terminal sialic acid residues and FcgammaRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur J Immunol44:1444-1453.
    Schwab, I., and F. Nimmerjahn. 2014. Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin – F(ab‘)(2) versus Fc sialylation. Clin Exp Immunol178 Suppl 1:97-99.
  • Schwartz, C., A. Turqueti-Neves, S. Hartmann, P. Yu, F. Nimmerjahn, and D. Voehringer. 2014. Basophil-mediated protection against gastrointestinal helminths requires IgE-induced cytokine secretion. Proc Natl Acad Sci U S A 111:E5169-5177.
  • Toh, M.L., J.Y. Bonnefoy, N. Accart, S. Cochin, S. Pohle, H. Haegel, M. De Meyer, C. Zemmour, X. Preville, C. Guillen, C. Thioudellet, P. Ancian, A. Lux, B. Sehnert, F. Nimmerjahn, R.E. Voll, and G. Schett. 2014. Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. Arthritis Rheumatol 66:2989-3000.
  • Aschermann, S., C.H. Lehmann, S. Mihai, G. Schett, D. Dudziak, and F. Nimmerjahn. 2013. B cells are critical for autoimmune pathology in Scurfy mice. Proc Natl Acad Sci U S A 110:19042-19047.
  • Glorius, P., A. Baerenwaldt, C. Kellner, M. Staudinger, M. Dechant, M. Stauch, F.J. Beurskens, P.W. Parren, J.G. Winkel, T. Valerius, A. Humpe, R. Repp, M. Gramatzki, F. Nimmerjahn, and M. Peipp. 2013. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. Leukemia27:190-201.
  • Lux, A., and F. Nimmerjahn. 2013. Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J Clin Immunol 33 Suppl 1:S4-8.
  • Lux, A., X. Yu, C.N. Scanlan, and F. Nimmerjahn. 2013. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 190:4315-4323.
  • Mihai, S., and F. Nimmerjahn. 2013. The role of Fc receptors and complement in autoimmunity. Autoimmun Rev 12:657-660.
  • Schwab, I., and F. Nimmerjahn. 2013. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nature Rev Immunol 13:176-189.
  • Seeling, M., U. Hillenhoff, J.P. David, G. Schett, J. Tuckermann, A. Lux, and F. Nimmerjahn. 2013. Inflammatory monocytes and Fcgamma receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A110:10729-10734.
  • Sehnert, B., H. Burkhardt, J.T. Wessels, A. Schroder, M.J. May, D. Vestweber, J. Zwerina, K. Warnatz, F. Nimmerjahn, G. Schett, S. Dubel, and R.E. Voll. 2013. NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immune-mediated diseases. Proc Natl Acad Sci U S A 110:16556-16561.
  • Straub, T., O. Schweier, M. Bruns, F. Nimmerjahn, A. Waisman, and H. Pircher. 2013. Nucleoprotein-specific nonneutralizing antibodies speed up LCMV elimination independently of complement and FcgammaR. Eur J Immunol 43:2338-2348.
  • Biburger, M., and F. Nimmerjahn. 2012. Low level of FcgammaRIII expression on murine natural killer cells. Immunol Lett 143:53-59.
    Bohm, S., I. Schwab, A. Lux, and F. Nimmerjahn. 2012. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 34:443-453.
  • Harre, U., D. Georgess, H. Bang, A. Bozec, R. Axmann, E. Ossipova, P.J. Jakobsson, W. Baum, F. Nimmerjahn, E. Szarka, G. Sarmay, G. Krumbholz, E. Neumann, R. Toes, H.U. Scherer, A.I. Catrina, L. Klareskog, P. Jurdic, and G. Schett. 2012. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791-1802.
  • Herrmann, M., C. Schafer, A. Heiss, S. Graber, A. Kinkeldey, A. Buscher, M.M. Schmitt, J. Bornemann, F. Nimmerjahn, L. Helming, S. Gordon, and W. Jahnen-Dechent. 2012. Clearance of fetuin-A–containing calciprotein particles is mediated by scavenger receptor-A. Circ Res 111:575-584.
  • Karsten, C.M., M.K. Pandey, J. Figge, R. Kilchenstein, P.R. Taylor, M. Rosas, J.U. McDonald, S.J. Orr, M. Berger, D. Petzold, V. Blanchard, A. Winkler, C. Hess, D.M. Reid, I.V. Majoul, R.T. Strait, N.L. Harris, G. Kohl, E. Wex, R. Ludwig, D. Zillikens, F. Nimmerjahn, F.D. Finkelman, G.D. Brown, M. Ehlers, and J. Kohl. 2012. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nature Med 18:1401-1406.
  • Kasperkiewicz, M., F. Nimmerjahn, S. Wende, M. Hirose, H. Iwata, M.F. Jonkman, U. Samavedam, Y. Gupta, S. Moller, E. Rentz, L. Hellberg, K. Kalies, X. Yu, E. Schmidt, R. Hasler, T. Laskay, J. Westermann, J. Kohl, D. Zillikens, and R.J. Ludwig. 2012. Genetic identification and functional validation of FcgammaRIV as key molecule in autoantibody-induced tissue injury. J Pathol 228:8-19.
  • Lehmann, B., I. Schwab, S. Bohm, A. Lux, M. Biburger, and F. Nimmerjahn. 2012. FcgammaRIIB: a modulator of cell activation and humoral tolerance. Expert Rev Clin Immunol8:243-254.
  • Lopez-Parra, V., B. Mallavia, O. Lopez-Franco, G. Ortiz-Munoz, A. Oguiza, C. Recio, J. Blanco, F. Nimmerjahn, J. Egido, and C. Gomez-Guerrero. 2012. Fcgamma receptor deficiency attenuates diabetic nephropathy. J Am Soc Nephrol 23:1518-1527.
  • Moldt, B., M. Shibata-Koyama, E.G. Rakasz, N. Schultz, Y. Kanda, D.C. Dunlop, S.L. Finstad, C. Jin, G. Landucci, M.D. Alpert, A.S. Dugast, P.W. Parren, F. Nimmerjahn, D.T. Evans, G. Alter, D.N. Forthal, J.E. Schmitz, S. Iida, P. Poignard, D.I. Watkins, A.J. Hessell, and D.R. Burton. 2012. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 86:6189-6196.
  • Nimmerjahn, F., and J.V. Ravetch. 2012. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 12:13.
  • Ruiz-Heiland, G., A. Horn, P. Zerr, W. Hofstetter, W. Baum, M. Stock, J.H. Distler, F. Nimmerjahn, G. Schett, and J. Zwerina. 2012. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 71:400-407.
  • Schwab, I., M. Biburger, G. Kronke, G. Schett, and F. Nimmerjahn. 2012. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 42:826-830.
  • Schwab, I., M. Seeling, M. Biburger, S. Aschermann, L. Nitschke, and F. Nimmerjahn. 2012. B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo. Eur J Immunol 42:3302-3309.
  • Uderhardt, S., M. Herrmann, O.V. Oskolkova, S. Aschermann, W. Bicker, N. Ipseiz, K. Sarter, B. Frey, T. Rothe, R. Voll, F. Nimmerjahn, V.N. Bochkov, G. Schett, and G. Kronke. 2012. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 36:834-846.

Lars Nitschke on Google Scholar

5 Key Publications

  1. Müller J, Nitschke L. (2014) The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol. 10:422-8.
  2. Schmitt H, Sell S, Koch J, Seefried M, Sonnewald S, Daniel C, Winkler TH, Nitschke L. (2016) Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med. 213:1627-44
  3. Müller J, Obermeier I, Wöhner M, Brandl C, Mrotzek S, Angermüller S, Maity PC, Reth M, Nitschke L. (2013) CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. Proc Natl Acad Sci U S A. 110:12402-7
  4. Ackermann J, Radtke D, Maurberger, A, Winkler TH, Nitschke L (2011) Grb2 regulates Bcell maturation, B cell memory responses and inhibits B cell Ca2+ signalling. EMBO J. 30:1621-1633
  5. Hoffmann A, Kerr S, Jellusova J, Zhang J, Weisel F, Wellmann U, Winkler TH, Kneitz B, Crocker PR, Nitschke L. (2007)  Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat Immunol. 8:695-704.

Primary Publications (since 2012)

  • Prescher H, Frank M, Gütgemann S, Kuhfeldt E, Schweizer A, Nitschke L, Watzl C, Brossmer R. (2017) Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion. J Med Chem. 60: 941-956
  • Schmitt H, Sell S, Koch J, Seefried M, Sonnewald S, Daniel C, Winkler TH, Nitschke L. (2016) Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med. 213:1627-44
  • Radtke D, Lacher SM, Szumilas N, Sandrock L, Ackermann J, Nitschke L, Zinser E. (2016) Grb2 Is Important for T Cell Development, Th Cell Differentiation, and Induction of Experimental Autoimmune Encephalomyelitis. J Immunol. 196:2995-3005
  • Krzyzak L, Seitz C, Urbat A, Hutzler S, Ostalecki C, Gläsner J, Hiergeist A, Gessner A, Winkler TH, Steinkasserer A, Nitschke L. (2016) CD83 Modulates B Cell Activation and Germinal Center Responses. J Immunol. 196:3581-94
  • Özgör L, Brandl C, Shock A, Nitschke L. (2016) Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22. Eur J Immunol. 46:2260-72
  • Gruber, S., Hendrikx, T., Tsiantoulas, D., Ozsvar-Kozma, M., Goderle, L., Mallat, Z., Witztum, J.L., Shiri-Sverdlov, R., Nitschke, L., and Binder, C.J. (2016). Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells. Cell Rep 14, 2348-2361.
  • Gasparrini, F., Feest, C., Bruckbauer, A., Mattila, P.K., Muller, J., Nitschke, L., Bray, D., and Batista, F.D. (2016). Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling. EMBO J 35, 258-280.
  • Nitschke L. (2015) Siglec-G is a B-1 cell inhibitory receptor and also controls B cell tolerance. Ann N Y Acad Sci. 1362:117-21
  • Übelhart R, Hug E, Bach MP, Wossning T, Dühren-von Minden M, Horn AH, Tsiantoulas D, Kometani K, Kurosaki T, Binder CJ, Sticht H, Nitschke L, Reth M, Jumaa H. (2015) Responsiveness of B cells is regulated by the hinge region of IgD. Nat Immunol. 16:534-43
  • Ludwig J, Federico G, Prokosch S, Küblbeck G, Schmitt S, Klevenz A, Gröne HJ, Nitschke L, Arnold B. (2015) Dickkopf-3 acts as a modulator of B cell fate and function. J Immunol. 194:2624-34.
  • Müller, J., Lunz, B., Schwab, I., Acs, A., Nimmerjahn, F., Daniel, C., and Nitschke, L. (2015). Siglec-G deficiency leads to autoimmunity in aging C57BL/6 mice. J Immunol195,51-60.
  • Engels N, König LM, Schulze W, Radtke D, Vanshylla K, Lutz J, Winkler TH, Nitschke L, Wienands J. (2014) The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module. Nat Commun. 5:5456.
  • Nitschke L. (2014) CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance. Glycobiology. 24:807-17.
  • Luo W, Mayeux J, Gutierrez T, Russell L, Getahun A, Müller J, Tedder T, Parnes J, Rickert R, Nitschke L, Cambier J, Satterthwaite AB, Garrett-Sinha LA. (2014) A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal Ets1 levels. J Immunol. 2014 Jul 15;193(2):909-20.
  • Simonetti G, Bertilaccio MT, Rodriguez TV, Apollonio B, Dagklis A, Rocchi M, Innocenzi A, Casola S, Winkler TH, Nitschke L, Ponzoni M, Caligaris-Cappio F, Ghia P. (2014) SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders. Haematologica. 99:1356-64.
  • Prescher H, Schweizer A, Kuhfeldt E, Nitschke L, Brossmer R. (2014) Discovery of multifold modified sialosides as human CD22/Siglec-2 ligands with nanomolar activity on B-cells. ACS Chem Biol. 9:1444-50.
  • Hutzler S, Özgör L, Naito-Matsui Y, Kläsener K, Winkler TH, Reth M, Nitschke L. (2014) The ligand-binding domain of Siglec-G is crucial for its selective inhibitory function on B1 cells. J Immunol. 192:5406-14.
  • Müller J, Nitschke L. (2014) The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol. 10:422-8.
  • Bökers S, Urbat A, Daniel C, Amann K, Smith KG, Espéli M, Nitschke L. (2014) Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice. J Immunol. 192:2994-3002.
  • Niedzielska M, Bodendorfer B, Münch S, Eichner A, Derigs M, da Costa O, Schweizer A, Neff F, Nitschke L, Sparwasser T, Keyse SM, Lang R. (2014) Gene trap mice reveal an essential function of dual specificity phosphatase Dusp16/MKP-7 in perinatal survival and regulation of Toll-like receptor (TLR)-induced cytokine production. J Biol Chem. 289:2112-26.
  • Naito-Matsui Y, Takada S, Kano Y, Iyoda T, Sugai M, Shimizu A, Inaba K, Nitschke L, Tsubata T, Oka S, Kozutsumi Y, Takematsu H. (2014) Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells. J Biol Chem. 289:1564-79.
  • Dütting S, Vögtle T, Morowski M, Schiessl S, Schäfer CM, Watson SK, Hughes CE, Ackermann JA, Radtke D, Hermanns HM, Watson SP, Nitschke L, Nieswandt B. (2014) Growth factor receptor-bound protein 2 contributes to (hem)immunoreceptor tyrosine-based activation motif-mediated signaling in platelets. Circ Res.114:444-53.
  • Nitschke L. (2013) Suppressing the antibody response with Siglec ligands. N Engl J Med. 369:1373-4.
  • Puttur F, Arnold-Schrauf C, Lahl K, Solmaz G, Lindenberg M, Mayer CT, Gohmert M, Swallow M, van Helt C, Schmitt H, Nitschke L, Lambrecht BN, Lang R, Messerle M, Sparwasser T. (2013) Absence of Siglec-H in MCMV infection elevates interferon alpha production but does not enhance viral clearance. PLoS Pathog. 9(9):e1003648.
  • Müller J, Obermeier I, Wöhner M, Brandl C, Mrotzek S, Angermüller S, Maity PC, Reth M, Nitschke L. (2013) CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. Proc Natl Acad Sci U S A. 110:12402-7.
  • Wöhner M, Born S, Nitschke L. (2012) Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model. Eur J Immunol.42: 3009-18
  • Schwab I, Seeling M, Biburger M, Aschermann S, Nitschke L, Nimmerjahn F. (2012) B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo. Eur J Immunol. 42:3302-9
  • Walker JA, Hall AM, Kotsopoulou E, Espeli M, Nitschke L, Barker RN, Lyons PA, Smith KG. (2012) Increased red cell turnover in a line of CD22-deficient mice is caused by Gpi1c: a model for hereditary haemolytic anaemia. Eur J Immunol. 42:3212-22
  • Schweizer A, Wöhner M, Prescher H, Brossmer R, Nitschke L. (2012) Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues. Eur J Immunol. 42:2792-802.

Thomas Winkler on Google Scholar

5 Key Publications

  1. Schmitt, H., S. Sell, J. Koch, M. Seefried, S. Sonnewald, C. Daniel, T.H. Winkler, and L. Nitschke. 2016. Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med213:1627-1644.
  2. Sell, S., M. Dietz, A. Schneider, R. Holtappels, M. Mach, and T.H. Winkler. 2015. Control of murine cytomegalovirus infection by gammadelta T cells. PLoS path11:e1004481.
  3. Pötzsch, S., N. Spindler, A.K. Wiegers, T. Fisch, P. Rucker, H. Sticht, N. Grieb, T. Baroti, F. Weisel, T. Stamminger, L. Martin-Parras, M. Mach, and T.H. Winkler. 2011. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS path 7:e1002172.
  4. Weisel, F.J., U.K. Appelt, A.M. Schneider, J.U. Horlitz, N. van Rooijen, H. Korner, M. Mach, and T.H. Winkler. 2010. Unique requirements for reactivation of virus-specific memory B lymphocytes. J Immunol185:4011-4021.
  5. Wellmann, U., M. Letz, M. Herrmann, S. Angermuller, J.R. Kalden, and T.H. Winkler. 2005. The evolution of human anti-double-stranded DNA autoantibodies. Proc Nat Acad Sci USA 102:9258-9263.

Primary Publications (since 2012)

  • Pfeifle, R., T. Rothe, N. Ipseiz, H.U. Scherer, S. Culemann, U. Harre, J.A. Ackermann, M. Seefried, A. Kleyer, S. Uderhardt, B. Haugg, A.J. Hueber, P. Daum, G.F. Heidkamp, C. Ge, S. Bohm, A. Lux, W. Schuh, I. Magorivska, K.S. Nandakumar, E. Lonnblom, C. Becker, D. Dudziak, M. Wuhrer, Y. Rombouts, C.A. Koeleman, R. Toes, T.H. Winkler, R. Holmdahl, M. Herrmann, S. Bluml, F. Nimmerjahn, G. Schett, and G. Kronke. 2017. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol 18:104-113.
  • Schmitt, H., S. Sell, J. Koch, M. Seefried, S. Sonnewald, C. Daniel, T.H. Winkler, and L. Nitschke. 2016. Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med 213:1627-1644.
  • Krzyzak, L., C. Seitz, A. Urbat, S. Hutzler, C. Ostalecki, J. Glasner, A. Hiergeist, A. Gessner, T.H. Winkler, A. Steinkasserer, and L. Nitschke. 2016. CD83 Modulates B Cell Activation and Germinal Center Responses. J Immunol196:3581-3594.
  • Sell, S., M. Dietz, A. Schneider, R. Holtappels, M. Mach, and T.H. Winkler. 2015. Control of murine cytomegalovirus infection by gammadelta T cells. PLoS path 11:e1004481.
  • Wiegers, A.K., H. Sticht, T.H. Winkler, W.J. Britt, and M. Mach. 2015. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus. J Virol 89:361-372.
  • Hammersen, J., J. Hou, S. Wunsche, S. Brenner, T. Winkler, and H. Schneider. 2015. A new mouse model of junctional epidermolysis bullosa: the LAMB3 628G>A knockin mouse. Journal invest dermatol 135:921-924.
  • Brachs, S., A. Turqueti-Neves, M. Stein, D. Reimer, B. Brachvogel, M. Bosl, T. Winkler, D. Voehringer, H.M. Jack, and D. Mielenz. 2014. Swiprosin-1/EFhd2 limits germinal center responses and humoral type 2 immunity. Eur J Immunol 44:3206-19.
  • Engels, N., L.M. Konig, W. Schulze, D. Radtke, K. Vanshylla, J. Lutz, T.H. Winkler, L. Nitschke, and J. Wienands. 2014. The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module. Nat comm 5:5456.
  • Lutz, J., K. Dittmann, M.R. Bosl, T.H. Winkler, J. Wienands, and N. Engels. 2015. Reactivation of IgG-switched memory B cells by BCR-intrinsic signal amplification promotes IgG antibody production Nat comm 6:8575.
  • Spindler, N., U. Diestel, J.D. Stump, A.K. Wiegers, T.H. Winkler, H. Sticht, M. Mach, and Y.A. Muller. 2014. Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody. PLoS path 10:e1004377.
  • Hutzler, S., L. Ozgor, Y. Naito-Matsui, K. Klasener, T.H. Winkler, M. Reth, and L. Nitschke. 2014. The ligand-binding domain of Siglec-G is crucial for its selective inhibitory function on B1 cells. J Immunol192:5406-5414.
  • Simonetti, G., M.T. Bertilaccio, T.V. Rodriguez, B. Apollonio, A. Dagklis, M. Rocchi, A. Innocenzi, S. Casola, T.H. Winkler, L. Nitschke, M. Ponzoni, F. Caligaris-Cappio, and P. Ghia. 2014. SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders. Haematologica 99:1356-1364.
  • Schroeder, K., M. Herrmann, and T.H. Winkler. 2013. The role of somatic hypermutation in the generation of pathogenic antibodies in SLE. Autoimmunity 46:121-127.
  • Song, J., Z. Lokmic, T. Lammermann, J. Rolf, C. Wu, X. Zhang, R. Hallmann, M.J. Hannocks, N. Horn, M.A. Ruegg, A. Sonnenberg, E. Georges-Labouesse, T.H. Winkler, J.F. Kearney, S. Cardell, and L. Sorokin. 2013. Extracellular matrix of secondary lymphoid organs impacts on B-cell fate and survival. Proc Nat Acad Sci USA110: 2915-2924.
  • Spindler, N., P. Rucker, S. Potzsch, U. Diestel, H. Sticht, L. Martin-Parras, T.H. Winkler, and M. Mach. 2013. Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus. J Virol 87:8927-8939.
  • Stein, M.F., S. Lang, T.H. Winkler, A. Deinzer, S. Erber, D.M. Nettelbeck, E. Naschberger, R. Jochmann, M. Sturzl, R.K. Slany, T. Werner, A. Steinkasserer, and I. Knippertz. 2013. Multiple interferon regulatory factor and NF-kappaB sites cooperate in mediating cell-type- and maturation-specific activation of the human CD83 promoter in dendritic cells. Mol Cell Biol33:1331-1344.
  • Wiede, F., P.D. Fromm, I. Comerford, E. Kara, J. Bannan, W. Schuh, C. Ranasinghe, D. Tarlinton, T. Winkler, S.R. McColl, and H. Korner. 2013. CCR6 is transiently upregulated on B cells after activation and modulates the germinal center reaction in the mouse. Immun Cell Biol91:335-339.
  • Schietke, R.E., T. Hackenbeck, M. Tran, R. Gunther, B. Klanke, C.L. Warnecke, K.X. Knaup, D. Shukla, C. Rosenberger, R. Koesters, S. Bachmann, P. Betz, G. Schley, J. Schodel, C. Willam, T. Winkler, K. Amann, K.U. Eckardt, P. Maxwell, and M.S. Wiesener. 2012. Renal tubular HIF-2alpha expression requires VHL inactivation and causes fibrosis and cysts. PloS one 7:e31034.

Robert Slany on Google Scholar

5 Key Publications

  1. Garcia-Cuellar MP, Büttner C, Bartenhagen C, Dugas C, Slany R.K. (2016) Leukemogenic MLL-ENL fusions induce alternative chromatin states to drive a functionally dichotomous group of target genes. Cell Reports, pii: S2211-1247(16)30259-5. doi: 10.1016/j.celrep.2016.03.018
  2. Bach C., and Slany R.K. (2014) DOTting the Path to Doom: How Acceleration of Histone Methylation Leads to Leukemia. Cancer Cell. 8;26(6):781-782.
  3. Garcia-Cuellar M.P., Füller E., Maethner E., Breitinger C., Hetzner K., Zeitlmann L., Borkhardt A., and Slany R.K. (2014) Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed lineage leukemia, Leukemia, 28, 1427–1435 (doi: 10.1038/leu.2014.40)
  4. Maethner E., Garcia-Cuellar M.P., Breitinger C., Takacova S., Divoky V., Hess J.L., and Slany R.K. (2013) MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells, Cell Reports, May 30;3(5):1553-66
  5. Müller D., Garcia-Cuellar M.P., Bach C., Buhl S., Mäthner E., and Slany R.K. (2009) Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia, PLOS Biology, 7(11):e1000249

Primary Publications (since 2012)

  • Wiersma M, Bussiere M, Halsall JA, Turan N, Slany R, Turner BM,  and Nightingale KP. (2016) Protein kinase Msk1 physically and functionally interacts with the KMT2A/MLL1 methyltransferase complex and contributes to the regulation of multiple target genes. Epigenetics Chromatin. 9:52.
  • Garcia-Cuellar MP, Büttner C, Bartenhagen C, Dugas C, Slany R.K. (2016) Leukemogenic MLL-ENL fusions induce alternative chromatin states to drive a functionally dichotomous group of target genes. CellReports, pii: S2211-1247(16)30259-5. doi: 10.1016/j.celrep.2016.03.018
  • Slany R.K. (2016) The molecular mechanics of mixed lineage leukemia, Oncogene, Review, Feb 29. doi: 10.1038/onc.2016.30
  • Nolte E, Sobel A, Wach S, Hertlein H, Ebert N, Müller-Uri F, Slany R, Taubert H, Wullich B, Kreis W. (2015) The New Semisynthetic Cardenolide Analog 3β-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines, Anticancer Res. 2015 Oct;35(10):5271-5.
  • Krumbholz M, Bradtke J, Stachel D, Peters O, Hero B, Holter W, Slany R, Metzler M. (2015) From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML. Bone Marrow Transplant. Oct;50(10):1382-4 doi: 10.1038/bmt.2015.155.
  • Woodcroft MW, Nanan K, Thompson P, Tyryshkin K, Smith SP, Slany R.K., LeBrun DP. (2015) Retrovirus-Mediated Expression of E2A-PBX1 Blocks Lymphoid Fate but Permits Retention of Myeloid Potential in Early Hematopoietic Progenitors. PLoS One. 10(6):e0130495. doi: 10.1371/journal.pone.0130495
  • Garcia-Cuellar M.P.,  Steger J., Füller E., Hetzner K, Slany R.K. (2015) Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia. Haematologica. Jul;100(7):905-913
  • Kaeda J., Ringel F., Oberender C., Mills K., Quintarelli C., Pane F., Koschmieder S., Slany R., Schwarzer R., Saglio G., Hemmati P., van Lessen A., Amini L., Greese M., Vagge E., Burmeister T., Serra A., Carson A., Schwarz M., Westermann J., Jundt F., Dörken B., le Coutre P. (2015) Upregulated MSI2 is associated with more aggressive leukemia. Leuk Lymphoma  Jan 23:1-9
  • Steger J., Füller, E., Garcia-Cuellar M.P., Hetzner K., and Slany R. K. (2015) Insulin like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation, Leukemia,  Apr;29(4):901-908
  • Bach C., and Slany R.K. (2014) DOTting the Path to Doom: How Acceleration of Histone Methylation Leads to Leukemia. Cancer Cell. 8;26(6):781-782.Füller E., Schäfer D., Fischer U., Krell P.F.I., Stanulla M., Borkhardt A. and Slany R. K. (2014) Genomic inverse PCR for exploration of ligated breakpoints (GIPFEL), a new method to detect translocations in leukemia, PLOSone, 9(8):e104419. doi: 10.1371/journal.pone.0104419
  • Garcia-Cuellar M.P., Füller E., Maethner E., Breitinger C., Hetzner K., Zeitlmann L., Borkhardt A., and Slany R.K. (2014) Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed lineage leukemia, Leukemia, 28, 1427–1435 (doi: 10.1038/leu.2014.40)
  • Maethner E., Garcia-Cuellar M.P., Breitinger C., Takacova S., Divoky V., Hess J.L., and Slany R.K. (2013) MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells, CellReports, May 30;3(5):1553-66
  • Stein M.F., Lang S., Winkler T.H., Deinzer A., Erber S. Nettelbeck D.M., Naschberger E., Jochmann R., Stürzl M., Slany R.K., Werner T., Steinkasserer A., and Knippertz I. (2013)  Multiple IRF- and NFkB-sites cooperate in mediating cell type- and maturation-specific activation of the human CD83 promoter in dendritic cells. Mol. Cell. Biol. Apr;33(7):1331-44
  • Breitinger C., Maethner E., Garcia-Cuellar M.P., Schambony A., Fischer K.D., Schilling K. and Slany R.K. (2013) HOX genes regulate Rac1 activity in hematopoietic cells through control of Vav2 expression, Leukemia,27(1):236-238
  • Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J (2012) miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia, PNAS, Nov 20;109(47):19397-402
  • Jiang X, Huang H, Li Z,  Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews J, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C, and Chen J. (2012) Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 22: 524-535
  • Breitinger C., Maethner E., Garcia-Cuellar M.P., and Slany R.K. (2012) The homeodomain region controls the phenotype of HOX-induced murine leukemia. Blood, 120(19):4018-4027
  • Dassé E, Volpe G, Walton DS, Wilson N, Del Pozzo W, O’Neill LP, Slany RK, Frampton J, Dumon S. (2012) Distinct regulation of c-myb gene expression by HoxA9, Meis1 and Pbx proteins in normal hematopoietic progenitors and transformed myeloid cells. Blood Cancer J. 2(6):e76
  • Takacova S., Slany R., Bartkova J., Stranecky V., Dolezel P., Luzna P., Bartek J., Divoky V. (2012) DNA Damage Response and Inflammatory Signaling Limit the MLL-ENL induced
    Leukemogenesis in vivo, Cancer Cell,21(4):517-531